Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Buy

Price to Earnings Rating

Neutral

Analyst Rating

Buy

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Buy

A

Entrada Therapeutics, Inc. Common Stock (TRDA)

Pharmaceutical Preparations

https://www.entradatx.com

Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.

ONE DESIGN CENTER PLACE, SUITE 17-500
BOSTON, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/29/2021

Market Cap

605,608,674

Shares Outstanding

33,369,999

Weighted SO

33,368,078

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

MOLN --.--%

PMVP --.--%

GLUE --.--%

VIGL --.--%

THRD --.--%

CGEM --.--%

EWTX --.--%

RLYB --.--%

CRNX --.--%

Beta

-0.2490

Last Div

0.0000

Range

10.75-18.17

Chg

0.0200

Avg Vol

116088

Mkt Cap

605608674

Exch

NASDAQ

Country

US

Phone

857 520 9158

DCF Diff

12.6453

DCF

0.1147

Div Yield

0.0000

P/S

2.5297

EV Multiple

5.0488

P/FV

1.2943

Div Yield %

0.0000

P/E

5.3278

PEG

0.0574

Payout

0.0000

Current Ratio

5.7049

Quick Ratio

5.7049

Cash Ratio

2.1589

DSO

13.8348

DIO

0.0000

Op Cycle

13.8348

DPO

177.0846

CCC

-163.2498

Gross Margin

0.9859

Op Margin

0.3904

Pretax Margin

0.4611

Net Margin

0.4363

Eff Tax Rate

0.0537

ROA

0.1795

ROE

0.3516

ROCE

0.1884

NI/EBT

0.9463

EBT/EBIT

1.1811

EBIT/Rev

0.3904

Debt Ratio

0.1107

D/E

0.1499

LT Debt/Cap

0.1150

Total Debt/Cap

0.1304

Int Coverage

-21.0243

CF/Debt

-1.3828

Equity Multi

1.3536

Rec Turnover

26.3827

Pay Turnover

2.0612

Inv Turnover

0.0000

FA Turnover

2.7288

Asset Turnover

0.4114

OCF/Share

-2.6072

FCF/Share

-2.7471

Cash/Share

13.7431

OCF/Sales

-0.3722

FCF/OCF

1.0537

CF Coverage

-1.3828

ST Coverage

-10.4021

CapEx Coverage

-18.6277

Div&CapEx Cov

-18.6277

P/BV

1.2943

P/B

1.2943

P/S

2.5297

P/E

5.3278

P/FCF

-6.4496

P/OCF

-6.2443

P/CF

-6.2443

PEG

0.0574

P/S

2.5297

EV Multiple

5.0488

P/FV

1.2943

DPS

0.0000

Latest Headlines (EST)

Zacks Investment Research Jan 03, 14:05 Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation Zacks Investment Research Dec 29, 11:45 Bayer (BAYRY) Loses 28% in 2023: What to Expect in 2024? Zacks Investment Research Dec 26, 11:32 Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate Benzinga Nov 27, 12:00 HC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To Know Benzinga Nov 22, 14:45 Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today? Benzinga Nov 22, 14:45 Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today?

Revenue Product Segmentation